Blancho G, Moreau J F, Chabannes D, Chatenoud L, Soulillou J P
Service de Néphrologie-Immunologie Clinique, CHU Nantes, France.
Transplantation. 1993 Sep;56(3):597-602. doi: 10.1097/00007890-199309000-00019.
HILDA/LIF, a recently described glycoprotein, has been characterized from supernatants of alloreactive T cell clones (CD4 and CD8) extracted from a human rejected kidney graft. This suggests a possible role for HILDA/LIF in the rejection process. In order to further investigate this possible role and the role of other cytokines in allograft rejection, we tested HILDA/LIF, G.CSF, IL-6, TNF alpha, and IL-1 beta in supernatants of cultured mononucleated cells from patients during rejection and from stable grafted patients. In addition, we also tested HILDA/LIF in urine of the same patients. No significant differences were directly observed in the production of HILDA/LIF, TNF alpha, and IL-1 beta in supernatants from mononucleated cells between rejecting and stable patients. However, when antibodies were used to block the TNF alpha and the IL-1 beta receptors, an increase of both cytokines was detected in cells from rejecting patients suggesting that an over-expression of both receptors and cytokines occurred during rejection. A significant increase was also observed for both G.CSF and IL-6 during the rejection compared to stable grafts. In addition, HILDA/LIF was detected in urine of patients during rejection and not in urine of stable patients, suggesting that this cytokine may indeed play a role in rejection.
HILDA/LIF是一种最近被描述的糖蛋白，已从取自人类移植肾排斥反应的同种异体反应性T细胞克隆（CD4和CD8）的上清液中得到鉴定。这表明HILDA/LIF在排斥反应过程中可能发挥作用。为了进一步研究这种可能的作用以及其他细胞因子在同种异体移植排斥反应中的作用，我们检测了排斥反应患者和移植稳定患者培养的单核细胞上清液中的HILDA/LIF、粒细胞集落刺激因子（G.CSF）、白细胞介素-6（IL-6）、肿瘤坏死因子α（TNFα）和白细胞介素-1β（IL-1β）。此外，我们还检测了同一患者尿液中的HILDA/LIF。在排斥反应患者和移植稳定患者的单核细胞上清液中，未直接观察到HILDA/LIF、TNFα和IL-1β产生的显著差异。然而，当使用抗体阻断TNFα和IL-1β受体时，在排斥反应患者的细胞中检测到这两种细胞因子均增加，这表明在排斥反应期间这两种受体和细胞因子均发生了过度表达。与移植稳定患者相比，排斥反应期间G.CSF和IL-6也显著增加。此外，在排斥反应患者的尿液中检测到了HILDA/LIF，而移植稳定患者的尿液中未检测到，这表明这种细胞因子可能确实在排斥反应中发挥作用。
